92results about "Proteoglycans" patented technology

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.

Provided herein are versikine nucleic acid molecules comprising at least 90% sequence identity to SEQ ID NO: 1. Also provided herein are pharmaceutical compositions comprising any one of the versikine nucleic acid molecules described herein, and a lipid nanoparticle, wherein the versikine nucleic acid molecule is encapsulated in the lipid nanoparticle. Any of the versikine compositions described herein can be used for the treatment of cancer.

The invention belongs to the field of medicines, and discloses application of a stress-induced stem cell extract in treatment of cerebral apoplexy. The inventor finds that stem cells are cultured under proper stress conditions through screening, and the separated stem cell extract (also known as Alritoin) can increase the axon length and dendritic length of normal primary neurons and is beneficial to growth and conduction of nerve fibers; in a pdMCAO model, the volume of cerebral infarction in the acute stage of ischemia of a mouse can be remarkably reduced, the neurological function score can be improved, and a relatively good improvement trend is achieved in the aspect of cognition; in the acute stage of cerebral ischemia reperfusion, the pharmaceutical composition has remarkable effects on reducing the cerebral infarction volume of a mouse, reducing relative edema and improving the neurological function, and is relatively long in medication time window; in a cerebral ischemia reperfusion model, the trend of improving local cerebral blood flow is shown. The allitoin is expected to be developed into a promising drug for cerebral apoplexy, especially a drug for treating ischemic cerebral apoplexy.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating Alzheimer's disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. According to the present invention, the mesenchymal stem cells are stimulated to express the protein with the nerve repair function through the ultraviolet irradiation stress mode, and the protein polymer is obtained through further separation and purification, such that the protein polymer can be adapted to diversified application modes, can improve the abnormal conditions of the Alzheimer's disease related biomarkers, and can provide the significant treatment effect on the Alzheimer's disease.

The present invention provides engineered T cells that express (a) a chimeric antigen receptor in which the antigen binding domain of the CAR binds to human GPC3 ("GPC-CAR"); and (b) an orthogonal receptor. The invention also provides methods of making and using such engineered T cells.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating spinal cerebellar ataxia disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. An ultraviolet irradiation stress mode is adopted, mesenchymal stem cells are stimulated to express protein with a neural repair function, the protein polymer is obtained through further separation and purification, the cell gene expression pathway is regulated, the cell stress state is relieved, the cells are promoted to recover normal forms and functions, meanwhile, the preparation mode is relatively simple, and the preparation method is suitable for large-scale production. And quality and yield monitoring is facilitated, and the method can be adapted to diversified application modes.

Provided is a method for simply and inexpensively producing a high-purity proteoglycan from a crushed product of cartilage tissue, a squeezed product of the crushed product, or an extract of the crushed product or the squeezed product.　In the present invention, a crushed product of cartilage tissue, a squeezed product of the crushed product, or an extract of the crushed product or the squeezed product is immersed in or added to an aqueous solution containing a salt, and an alcohol is added to the obtained liquid composition in such an amount as to have a final concentration of 10-60 vol%, whereby a proteoglycan is precipitated. Alternatively, a crushed product of cartilage tissue, a squeezed product of the crushed product, or an extract of the crushed product or the squeezed product is immersed in or added to an aqueous solution containing a salt and an alcohol in such an amount as to have a final concentration of 10-60 vol%, whereby a proteoglycan is precipitated.

The present invention provides a novel protein specifically binding to calreticulin and having the scaffold of human fibronectin domain III and a use thereof, wherein the protein can be used for diagnosing cell damage in an early stage to early determine cancer therapy effects and rapidly evaluate in vivo toxicity, thus finding advantageous applications as a candidate material for probes for in vivo diagnosis and treatment of cancer.

A mesoangioblast composition is disclosed, in which the mesoangioblasts (MABs) are engineered to express a truncated agrin protein.

Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.

Provided herein are versikine fusions, including versikine fusions with GM-CSF, CCL5, XCL1, FLT3L, CCL7, CXCL9, CXCL10, IL-12, IL-27, IL-15, IL18, IL-23, IL-2, IFN, as well as secretory peptides. Additionally, provided herein are methods for introducing versikine and versikine fusion proteins to cells, in vitro and in vivo. Additionally, provided herein are methods of treating cancer, increasing T cell activation in a tumor microenvironment (TME), or sensitizing a response to an immunotherapy in a subject in need thereof, the method comprising administering a proteolytic fragment of an extracellular matrix (ECM) proteoglycan.

This new chimeric antigen receptor (CAR) T-cell therapy effectively treats cancer while minimizing the risk of dangerous inflammatory responses such as cytokine release syndrome. [Solution] An isolated nucleic acid sequence encoding a CAR, wherein the CAR includes an antigen-binding domain specific to glypican 3 (GPC3), the antigen-binding domain has an equilibrium dissociation constant (KD) of approximately 100 nanomoles (nM) or less, and the CAR construct provides an isolated nucleic acid sequence that does not induce cytokine production in GPC3-expressing cells.

A mesoangioblast composition is disclosed, in which the mesoangioblasts (MABs) are engineered to express a truncated agrin protein.

The invention is based in part on the identification of PTK7 as a signalling receptor for C-terminal (domains III-IV) CCN2, and in part on the finding that GPC-1 and GPC-4 may act (individually or in combination) as coreceptors for CCN ligands. The invention relates to the therapeutic use of agents that bind to PTK7 and have PTK7 antagonist activity, agents that inhibit expression of PTK7, agents comprising a PTK polypeptide or a fragment thereof, agents that bind to a GPC coreceptor for CCN ligand and thus inhibit formation of GPC-CCN ligand-PTK7 complexes, agents that inhibit expression of GPCs, or agents comprising a GPC polypeptide or fragment thereof. The invention also relates to pharmaceutical compositions comprising such agents, and screening methods for their identification.

In the field of biological therapy, a major hurdle is the need for a platform technology that enables high bioavailability and long therapeutic exposure of a biological therapy in the setting of localized disease. Classical approaches result in problematic trade-offs such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST) which are able to bind biological structures, such as the extracellular matrix, through heparan sulfates, without bearing the undesirable neutralizing effects on activin A, myostatin, and GDF11 activities of e.g. full-length follistatin. The invention relates to fusion proteins or conjugated proteins, and compositions thereof, constructs or vectors encoding thereof, medical uses thereof and methods for biological therapy.

A protein polymer and a production process therefor. The protein polymer is obtained by means of stimulating MSCs, lysing same, and separating and purifying same. The protein polymer has a strong capability to repair oxidative damage, and thus can reduce the range of cerebral infarction, improve neural functions, inhibit the level of neuroinflammation, and increase the number of surviving neurons.

Provided are a use of recombinant calreticulin in hair growth, hair breeding, hair protection or anti-hair loss and a related product. The recombinant protein is derived from the full length of calreticulin or a fragment thereof, and has the functions of treating hair loss and improving hair by means of injection or application. Therefore, calreticulin is expected to be developed into an effective method and means for treating hair loss and improving hair.

The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and / or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and / or treating a hematological cancer in a subject.

Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 (“a GPC-CAR”); and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells.

The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.

The disclosure provides amino acid sequences (e.g., antibodies) that can bind Glypican 3 Protein (GPC3). The disclosure relates to antigen binding fragments of GPC3 antibodies, conjugates, including immunoconjugates, of GPC3 antibodies, bispecific antibodies that include GPC3 antibodies, and related compositions and formulations. The disclosure also relates to methods for using the sequences, e.g., GPC3 antibodies and antigen-binding fragments thereof, in the treatment of GPC3-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, and more particularly, liver cancer.

The purpose of the present invention is to provide a production method whereby a heparin-like substance is efficiently produced without using an animal-derived tissue. The present invention pertains to a method for producing a heparin-like substance, etc., said method comprising: (1) a step for preparing mammalian cells producing the heparin-like substance; (2) a step for preparing recombinant cells wherein a gene encoding the extracellular domain of syndecan is introduced into the heparin-like substance-producing mammalian cells prepared in step (1); and (3) a step for culturing the recombinant cells prepared in step (2) in a medium and collecting the heparin-like substance from the culture supernatant thus obtained.

To provide a method for producing proteoglycan that can produce proteoglycan in a simpler manner than conventional methods for producing proteoglycan and can produce proteoglycan in which a core protein is bound to a sugar chain.SOLUTION: The method for producing proteoglycan disclosed herein includes an extraction step of extracting an extract containing proteoglycan from an animal tissue, the proteoglycan containing a core protein and a glycan, and the core protein and the glycan being bound to each other.SELECTED DRAWING: Figure 4

The presently claimed and described technology provides vaccine compositions comprising at least two mutant-calreticulin (CALR)-peptides, wherein the at least two peptides have overlapping sequences and methods for administration of the vaccine compositions to induce or elicit an antitumor response or improve or enhance antitumor T cell immunity and methods of preventing, treating, reducing, or slowing progression or development of a hematological malignancy in a subject with a calreticulin mutation.

The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and / or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

Provided is an application of a protein polymer in the preparation of a drug for treating autism. Research has found that protein polymers derived from mesenchymal stem cells stimulated under stress conditions, such as ultraviolet irradiation, have a certain therapeutic effect on autism, providing a possibility for the treatment of autism.

The present disclosure provides an agent capable of reducing endotoxin and used for reducing endotoxin in animal tissue-derived proteoglycan, and a method for producing proteoglycan and capable of reducing endotoxin. The agent of the present disclosure for reducing endotoxin in the animal tissue-derived proteoglycan comprises a nonionic surfactant.

The present invention provides a simple, low-cost method for producing highly pure proteoglycan from a crushed cartilage tissue, a squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product. The crushed cartilage tissue, the squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product is immersed in or added to an aqueous solution containing salt, and alcohol is added to the resulting liquid composition in an amount to give a final concentration of 10 to 60% by volume to precipitate proteoglycans; alternatively, the crushed cartilage tissue, the squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product is immersed in or added to an aqueous solution containing salt and alcohol in an amount to give a final concentration of 10 to 60% by volume to precipitate proteoglycans.

The present invention relates to the use of MayDay peptide fragments designated decorin 31-170, decorin 31-188, decorin 31-177, decorin 31-169, or decorin 1-188 (the N-terminal fragment of the decorin protein) in the treatment and prevention of soft tissue inflammation and related disorders such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, osteoarthritis, anal fistula, and lupus. Methods of modulating tissue repair and modulating stem cell mobilization are also contemplated in the present invention.

Provided are engineered T cells that express (a) a chimeric antigen receptor ("GPC-CAR"), where the antigen-binding domain of the CAR binds to human GPC3, and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells. TIFF2025509288000067.tif39170